Qiagen (NASDAQ:QGEN) was upgraded by stock analysts at BidaskClub from a “sell” rating to a “hold” rating in a research report issued on Friday, January 5th.
Other research analysts have also recently issued research reports about the stock. TheStreet upgraded shares of Qiagen from a “c+” rating to a “b+” rating in a research note on Tuesday, November 7th. Commerzbank reissued a “buy” rating on shares of Qiagen in a report on Tuesday, December 12th. Deutsche Bank reissued a “buy” rating on shares of Qiagen in a report on Wednesday, November 8th. Zacks Investment Research raised shares of Qiagen from a “hold” rating to a “buy” rating and set a $39.00 price target for the company in a report on Tuesday, October 10th. Finally, Cowen reissued a “hold” rating and issued a $33.00 price target on shares of Qiagen in a report on Friday, November 3rd. One analyst has rated the stock with a sell rating, eight have given a hold rating and five have issued a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus target price of $34.63.
Shares of Qiagen (QGEN) traded up $0.46 on Friday, reaching $32.65. 723,291 shares of the company’s stock were exchanged, compared to its average volume of 998,460. The company has a market capitalization of $7,540.00, a PE ratio of 83.72, a price-to-earnings-growth ratio of 1.80 and a beta of 1.10. The company has a current ratio of 5.33, a quick ratio of 4.78 and a debt-to-equity ratio of 0.68. Qiagen has a 1 year low of $27.51 and a 1 year high of $36.34.
Qiagen (NASDAQ:QGEN) last announced its quarterly earnings results on Monday, November 6th. The company reported $0.32 EPS for the quarter, hitting analysts’ consensus estimates of $0.32. Qiagen had a net margin of 6.40% and a return on equity of 11.36%. The firm had revenue of $364.00 million during the quarter, compared to analysts’ expectations of $363.42 million. During the same quarter last year, the company earned $0.29 earnings per share. The company’s revenue for the quarter was up 7.5% compared to the same quarter last year. analysts expect that Qiagen will post 1.25 earnings per share for the current fiscal year.
Hedge funds have recently made changes to their positions in the company. Fox Run Management L.L.C. acquired a new position in shares of Qiagen in the 3rd quarter valued at $753,000. OxFORD Asset Management LLP grew its holdings in shares of Qiagen by 6.7% in the 3rd quarter. OxFORD Asset Management LLP now owns 81,216 shares of the company’s stock valued at $2,558,000 after buying an additional 5,116 shares during the period. Assenagon Asset Management S.A. acquired a new position in shares of Qiagen in the 3rd quarter valued at $10,110,000. AXA lifted its position in Qiagen by 5.0% in the 3rd quarter. AXA now owns 405,798 shares of the company’s stock valued at $12,783,000 after acquiring an additional 19,268 shares in the last quarter. Finally, Cubist Systematic Strategies LLC lifted its position in Qiagen by 27.7% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 16,208 shares of the company’s stock valued at $543,000 after acquiring an additional 3,519 shares in the last quarter. 62.09% of the stock is owned by institutional investors.
COPYRIGHT VIOLATION WARNING: “Qiagen (NASDAQ:QGEN) Stock Rating Upgraded by BidaskClub” was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this story on another site, it was stolen and reposted in violation of U.S. & international copyright and trademark law. The legal version of this story can be viewed at https://www.dispatchtribunal.com/2018/01/13/qiagen-qgen-upgraded-by-bidaskclub-to-hold.html.
Qiagen Company Profile
QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials.
Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.